Marc O’Reilly is Vice President Molecular Sciences and joined Astex in 2000. Over the past 20 years he has helped to establish and evolve Astex’s Fragment-Based Drug Discovery (FBDD) platform, which continues to deliver drug candidates for unmet medical needs in oncology and CNS. The Molecular Sciences Team now encompasses crystallography, cryo-electron microscopy, NMR, other biophysical methods and bioinformatics and supports the full breadth of Astex’s discovery pipeline. Marc has worked on numerous drug discovery programs, including that which led to Novartis’ launched oncology drug Kisqali®, and was instrumental in the discovery project that lead to ASTX029, which is currently in clinical development. Marc has more than 25 peer reviewed publications and patent applications, and is an active participant in pharmaceuticals circles as a member of the organising committee for the Cambridge New Therapeutics Forum (CamNTF).
Marc received a degree in Physics from Imperial College, London and a DPhil in Structural Biology from the University of Oxford. He joined Astex from a post-doctoral position at the MRC Laboratory of Molecular Biology (LMB), Cambridge.